Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Robin Foà, Renato Bassan, Antonella Vitale, +17

New England Journal of Medicine

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Robin Foà, Antonella Vitale, Marco Vignetti, +21

Blood

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol

Marco Vignetti, Paola Fazi, Giuseppe Cimino, +14

Blood

<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i> –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

Giovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, +17

Journal of Clinical Oncology

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

Sara Raponi, Maria Stefania De Propris, Stefania Intoppa, +7

Leukemia & lymphoma/Leukemia and lymphoma

Mixed-phenotype Acute LeukemiaImmunologyPathologyImmunophenotypingImmunotherapy +16

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Robin Foà, Renato Bassan, Loredana Elia, +13

Journal of Clinical Oncology

Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias.

Giuseppe Cimino, Maria Cristina Rapanotti, Andrea Biondi, +9

PubMed

Mixed-phenotype Acute LeukemiaGeneticsPathologyEpigeneticsInfant Leukemias +14

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Anna Lucia Fedullo, Monica Messina, Loredana Elia, +15

Haematologica

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Sabina Chiaretti, Monica Messina, Irene Della Starza, +32

Haematologica

Poor OutcomeMixed-phenotype Acute LeukemiaImmunologyPathologyEarly Recognition +14

E2A–PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features

Robin Foà, Antonella Vitale, Marco Mancini, +17

British Journal of Haematology

Mixed-phenotype Acute LeukemiaImmunologyCommon AllPathologyClinical Features +15